Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial ...

A ceramide-containing skin care regimen improves symptoms and quality of life in patients with atopic dermatitis, psoriasis, and xerosis.

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Announcing a new publication for Acta Materia Medica journal. Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents ...

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

J&J announces positive data from phase 3 ICONIC-TOTALa study of icotrokinra to treat scalp and genital psoriasis: Spring House, Pennsylvania Monday, May 12, 2025, 11:00 Hrs [IST] ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...